Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 - Wikidata - wikimedia - TriplyDB

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

http://www.wikidata.org/entity/Q35779325

about

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma Patient-derived xenograft models of breast cancer and their predictive power Prioritizing therapeutic targets using patient-derived xenograft models The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.Assessing the Racial and Ethnic Disparities in Breast Cancer Mortality in the United States Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1 Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1.Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.Calcium trafficking integrates endoplasmic reticulum function with mitochondrial bioenergetics HER2 phosphorylates and destabilizes pro-apoptotic PUMA, leading to antagonized apoptosis in cancer cells Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?Progress in breast cancer research.Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression.Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells The BCL-2 protein family, BH3-mimetics and cancer therapy.Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxel.Bcl-xL controls a switch between cell death modes during mitotic arrest Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells.Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line.γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Broad targeting of resistance to apoptosis in cancer.Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment.Nanotechnology inspired tools for mitochondrial dysfunction related diseases.MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer Mitochondria: gatekeepers of response to chemotherapy MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma.Ulva lactuca polysaccharides prevent Wistar rat breast carcinogenesis through the augmentation of apoptosis, enhancement of antioxidant defense system, and suppression of inflammation.Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases Triple-negative breast cancer: making the most of a misnomer.Therapeutic targets in triple negative breast cancer.Emerging drugs and combination strategies for basal cell carcinoma.Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.

P2860

Q26767435-483D90A2-8999-4794-9063-F1F05CDEF2A6 Q27026531-E6B3AF80-A58D-4C8E-9C24-D869EA7D7DD9 Q28083993-29B528BE-4463-4521-9134-8B35E482BAC6 Q30648719-FBAECCED-758D-484A-B6D5-6A8161101447 Q33418086-9A44CC2C-7693-4A2E-8ED3-D1386B5D9B6F Q33745649-292E64F9-B075-4E44-BD13-AC7B49AE1AA4 Q33748595-8F5789F0-599E-4EFE-824F-01847E66D684 Q33767497-977B40D9-95E5-4845-8865-1E6AB7483930 Q33924886-F72A4AA9-56DE-4689-A441-857C12874883 Q34374169-B05AED79-9A3A-48BC-9BD9-694D01381149 Q34489153-EE1EF892-399A-431D-8E20-F52C9B3A5A58 Q34793542-FB9B5B47-3CCD-4DDC-A49A-13CB8980FF7A Q34841551-D2E4242B-3373-43A2-9BC6-55FCA491A716 Q35043596-98B0F112-2788-40A0-9B7E-9A5B1BC6B43C Q35551802-1E495B11-4090-4351-9A8A-3D3B42CCAECF Q35779144-A11F24B9-ECDE-462C-9E15-1A4F2ADBCC4F Q35809680-CB9A009A-57E2-40B6-9E6F-65FA64A62C6F Q35828588-8BEB1A1A-F544-4151-AEFF-739DD2450437 Q36057611-6ED7B8E7-2759-4C40-9CCE-AE743CBBCE29 Q36067778-F6A2E018-DD31-43DF-8FFC-9A02E898F6C5 Q36081102-4E18501A-5B3A-4797-908C-650E9D31549F Q36179601-132A273D-9E39-46E2-8D31-969F8DA41536 Q36217154-5D45899A-5183-41A0-8907-A3C6B20497ED Q36243013-4D755E0F-6A80-4B18-8D07-A3346ECC8137 Q36245449-C3D2A093-36F9-4519-B905-301788E90DF3 Q36284637-9C96D175-6EFC-41FC-8CFA-280C68435BFB Q36483749-4783FD31-3DFF-46D8-8225-285EA082C20E Q36567569-B42FCB9C-B226-4B7E-897E-63B931A45CD0 Q36703351-36682BB2-709A-45ED-8363-7A13B65BD35F Q36928457-7A50AB9E-4C41-4A05-949B-B2FC69670296 Q37146398-EB2E9D0E-641F-462E-8EF6-103C3EDFBCD6 Q37347485-BD0926EC-9DBC-4EF3-945B-1D272464590E Q37487789-7B1F3D6F-9434-47D4-8167-4E9B9A30EAFF Q37613723-28DEE0B7-A6FB-440D-82A7-FED9680AC236 Q37684654-5A78909B-5D75-49B0-AF7A-DC9F22513F9F Q37921609-0A80449E-2105-4503-93E6-D51748E791CF Q38004606-6997951F-22D8-47DD-AAB8-F95F7466E42D Q38084287-35F78D7D-0853-462D-A8AA-BB767068FA67 Q38207707-2F0967DF-3114-4D03-AAAB-8F54A3EA4736 Q38563530-C126CC93-7DE9-46C3-B1C9-2E3C05D15A96

P2860

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

http://www.wikidata.org/entity/Q35779325

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Sensitization of BCL-2-express ...... apy by the BH3 mimetic ABT-737

@ast

Sensitization of BCL-2-express ...... apy by the BH3 mimetic ABT-737

@en

type

label

Sensitization of BCL-2-express ...... apy by the BH3 mimetic ABT-737

@ast

Sensitization of BCL-2-express ...... apy by the BH3 mimetic ABT-737

@en

prefLabel

Sensitization of BCL-2-express ...... apy by the BH3 mimetic ABT-737

@ast

Sensitization of BCL-2-express ...... apy by the BH3 mimetic ABT-737

@en

P1433

Q35779325-FCC77205-806A-44C4-A97D-13E581A93BC4

P1476

Q35779325-48E1BC92-D787-47A7-8279-340425343ABB

P2093

Q35779325-05901645-B6B5-4D2C-BC3E-C94539E526C0

Q35779325-5A6E0D22-99EE-4175-B12D-0D8A18283A4A

Q35779325-5E6E2BB3-F49F-413A-8150-08379C48D079

Q35779325-86E3B6A0-1C37-4B5D-B071-FDB30C6E7F4B

Q35779325-8EA8F93B-A6C2-4890-A6FD-9CF0AF3C6C6C

Q35779325-9FB9C8D9-E1B5-4C96-81A4-9397455393E3

Q35779325-B9539A40-E3A7-426B-A0CB-C5E088B15F61

Q35779325-EB4CFD14-FE97-4444-AF25-220A657C7C97

Q35779325-F23B1E73-BFC1-4B84-9B0E-C5F4D4D813EC

P2860

Q35779325-01EDDD56-E465-4D23-B703-F85D5ECDA000

Q35779325-09D28DC2-8748-49FA-BCC5-6E46E57D8B8E

Q35779325-15CC6824-4D0E-46CB-8B72-116C8CB6CF78

Q35779325-2758A841-9EA1-4C17-A4C9-0B9F6124D84D

Q35779325-3866A113-9B43-42C8-B5F8-836213E4358C

Q35779325-3B184B24-F907-460E-9411-5DAE1E468336

Q35779325-3D7A2F63-F565-4F00-96F0-11F26205DBBB

Q35779325-45337C0D-043F-4142-804A-199BD3BBEBF7

Q35779325-46F7E64F-ADFE-4FD7-BCE8-B85ADBABC606

Q35779325-4712ABAA-9540-4228-B9C9-D78BA8748242

P304

Q35779325-8E634388-551A-4F16-A79B-05B1085E971C

P31

Q35779325-3D5D870D-7E37-459D-B8C1-43D8BACADB6B

P356

Q35779325-E5149D6F-0F3F-4276-90D4-6688DECA35F8

P407

Q35779325-FD16D5D7-698F-4F4F-A9B5-93451477B230

P433

Q35779325-28896B6E-D1D7-4D8D-BD5B-3F183BE4FF25

P478

Q35779325-B8ED62BA-E37D-4B12-BB58-629383DD6797

P50

Q35779325-1AE1B64B-70A3-4168-A9C0-6A406C091E27

Q35779325-3E96B14C-435E-4624-B6CD-5E049C7DC564

Q35779325-4169CF9F-815F-41B5-937C-1C73779B9E6B

Q35779325-60CEA112-23B4-4F37-8207-BA63255FB516

Q35779325-7C467E13-B469-43CF-B069-D5539444BC87

Q35779325-C647CC46-8C8A-47FF-A392-E64E05E351DD

Q35779325-F8C99C6F-2BBD-4CC5-AB3E-9AF94E944A93

Q35779325-FB514866-47EA-44AA-AF3D-D407C4BD6330

P577

Q35779325-DF35C63F-91C9-4A14-9763-CB6D4A6CFA78

P5875

Q35779325-A33F7F96-88D4-412E-AA4E-C4270984FFB4

P698

Q35779325-9D5AC2F7-9818-49D2-BCC8-A4F831CF76A0

P921

Q35779325-622BD1C8-49D0-4AD5-9BA9-1161E169F7F1

P932

Q35779325-51DCE2E0-E151-4182-B209-D1236F1F20B9

P356

PNAS.1104778108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Sensitization of BCL-2-express ...... apy by the BH3 mimetic ABT-737

@en

P2093

David C S Huang

http://www.w3.org/2001/XMLSchema#string

Elena Takano

http://www.w3.org/2001/XMLSchema#string

Frank Feleppa

http://www.w3.org/2001/XMLSchema#string

François Vaillant

http://www.w3.org/2001/XMLSchema#string

Jane E Visvader

http://www.w3.org/2001/XMLSchema#string

Kelsey Breslin

http://www.w3.org/2001/XMLSchema#string

Lily Lee

http://www.w3.org/2001/XMLSchema#string

Siddhartha Deb

http://www.w3.org/2001/XMLSchema#string

Teresa Ward

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

The Bcl-2 apoptotic switch in cancer development and therapy

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

P304

2766-2771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1104778108

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Matthew E Ritchie

Andreas Strasser

Geoffrey J. Lindeman

Daniele Generali

Samantha R Oakes

P577

2011-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51501463

http://www.w3.org/2001/XMLSchema#string

P698

21768359

http://www.w3.org/2001/XMLSchema#string

P921

P932

3286989

http://www.w3.org/2001/XMLSchema#string